Conferences
High Cure Rate, Low Toxicity Maintained with Shortened Radiation Treatment for Intermediate Risk Prostate Cancer, Study Finds
October 2, 2023
ASTRO 2023: Prognostication of Overall Survival in Muscle Invasive Bladder Cancer: An Application of a Lymph Node Metastasis Nomogram
October 2, 2023
ASTRO 2023: Personalizing ADT Use in the Definitive Treatment of Intermediate Risk Prostate Cancer and Early Salvage Setting
October 2, 2023
ASTRO 2023: Prospective Comparative Study of Quality of Life in Bladder Cancer Patients Undergoing Cystectomy or Bladder Preservation
October 1, 2023
ASTRO 2023: Stereotactic Ablative Radiotherapy Boost to Bladder Tumor for Bladder Preservation in Patients with Muscle-Invasive Bladder Cancer
October 1, 2023
ASTRO 2023: Outcomes of MR-Guided Stereotactic Body Radiotherapy for Adrenal Metastases: A Multi-Institutional Pooled Analysis
October 1, 2023
ASTRO 2023: Single Dose Compared to Fractionated High-Dose Rate Afterloading Brachytherapy in Localized Prostate Cancer: Long Term Results
October 1, 2023
IBCN 2023: A Composite Biomarker Approach to Spare Neoadjuvant Chemotherapy in Select Muscle-Invasive Bladder Cancer Patients
October 1, 2023
IBCN 2023: Molecular Signatures Predict GEMDOCE Responses for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
October 1, 2023
IBCN 2023: Simulating The Effects of Molecular Urine Markers In Follow-Up Of Patients With High Risk Non-Muscle Invasive Bladder Cancer
October 1, 2023
IBCN 2023: Added Value of ctDNA Testing For Identifying FGFR3 Alterations In Metastatic Urothelial Cancer Eligible For Erdafitinib Treatment
October 1, 2023
IBCN 2023: Gene Expression-Based Classification of Urothelial Carcinoma For Research And Clinical Applications
October 1, 2023
IBCN 2023: Alignment Of Molecular Subtypes Across Multiple Bladder Cancer Subtyping Classifiers
October 1, 2023